French company BioCorp has announced a partnership agreement with Danish pharmaceutical firm Novo Nordisk for the commercialisation of Mallya, initially in Japan.

This new agreement is reinforcing the partnership between Novo Nordisk and BioCorp focused on development of the Mallya product announced in September 2021. This first development agreement was covering brands in the insulin space only, an additional therapeutic area in which Novo Nordisk has a presence has been included earlier this year.

Mallya (a non-medical device in Japan) is a smart sensor that directly attaches to the Novo Nordisk FlexTouch insulin pens. Mallya will enable patients with diabetes using FlexTouch pens to automatically collect and record daily insulin injection data such as the number of insulin units, the date, and the time. Thanks to a mobile application linked to Mallya, patients will be able to track their injection history and follow their treatment in real-time. Mallya is compatible with all Novo Nordisk FlexTouch insulin pens.

Based on the agreement, Novo Nordisk will be commercialising Mallya in Japan from the first half of 2023.